US 12,448,624 B2
Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
Jung Hwan Lee, Gyeonggi-do (KR); and Jong Ook Lee, Gyeonggi-do (KR)
Assigned to INTEROLIGO CORPORATION, Gyeonggi-do (KR)
Appl. No. 17/286,655
Filed by INTEROLIGO CORPORATION, Gyeonggi-do (KR)
PCT Filed Oct. 21, 2019, PCT No. PCT/KR2019/013834
§ 371(c)(1), (2) Date Apr. 19, 2021,
PCT Pub. No. WO2020/080912, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,807, filed on Oct. 19, 2018.
Claims priority of application No. 10-2019-0130669 (KR), filed on Oct. 21, 2019.
Prior Publication US 2021/0388361 A1, Dec. 16, 2021
Int. Cl. C12N 15/115 (2010.01); A61K 47/42 (2017.01); A61P 35/00 (2006.01)
CPC C12N 15/115 (2013.01) [A61K 47/42 (2013.01); A61P 35/00 (2018.01)] 11 Claims
OG exemplary drawing
 
1. An oligonucleotide variant having a structure of Formula 1 below:
 
 [Formula 1]
 
 (N)x-[TGG]m[TTG][TGG]n-(M)y
wherein, N and M are independently deoxyuridine (dU), deoxycytidine (dC), uridine (U), or cytidine (C), in which a halogen or hydroxy group is bound to 5- or 2′-position thereof; x and y are independently integers of 0 to 10 with a proviso that x and y are not simultaneously 0, n is an integer of 4 to 6; and m is an integer of 4 to 6.